))
Building Biotech at the Interface: Geoff Duyk on Genomics, Platforms, and Grove Biopharma_e.67
Manage episode 478787874 series 3006114
Content provided by John Flavin. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by John Flavin or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this episode of Lab Rats to Unicorns, host John Flavin speaks with Dr. Geoff Duyk, co-founder and CEO of Grove Biopharma. Geoff brings over 35 years of experience across academia, biotech leadership, and venture capital. From his early work in human genetics at UCSF to co-founding Millennium Pharmaceuticals and leading R&D at Exelixis, Geoff unpacks the evolution of biotech from the 1970s to today.
This conversation comes on the heels of Grove’s massive $30M Series A. Geoff shares the story behind Grove Biopharma’s founding, born from a collaboration between a Northwestern chemist, a green chemistry innovator, and himself—culminating in a startup focused on intracellular targets using novel protein-mimetic polymers. Geoff also reflects on the infrastructure and cultural foundations that make biotech innovation possible, from the NIH’s visionary investments to the importance of people, timing, and place. Learn how Grove is challenging the limits of drug design with a new class of molecules that behave like antibodies but operate inside cells—unlocking new frontiers in cancer and beyond.
70 episodes
Share
